Showing results (131-140 of 609) with videos related to
Sort By:
Pageof 61
Urology|November 20, 2003
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancerMasood A Khan, Alan W Partin, Leslie A Mangold, et al.The Journal of Urology|January 25, 2003
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancerMisop Han, Alan W Partin, Marianna Zahurak, et al.Cancer|February 23, 2007
Radical prostatectomy for clinical stage T3a diseaseStephen J Freedland, Alan W Partin, Elizabeth B Humphreys, et al.The Urologic Clinics of North America|November 29, 2015
Urinary Biomarkers for Prostate CancerJeffrey J Tosoian, Ashley E Ross, Lori J Sokoll, et al.Urology|July 15, 2010
Prediction of mortality after radical prostatectomy by Charlson comorbidity indexThomas J Guzzo, Paul Dluzniewski, Ryan Orosco, et al.The Journal of Urology|March 23, 2011
Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasiaLance A Mynderse, Claus G Roehrborn, Alan W Partin, et al.Cancer|October 8, 2004
Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomyCraig G Rogers, Masood A Khan, M Craig Miller, et al.Transactions of the American Clinical and Climatological Association|January 10, 2017
CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENSAlan W Partin, Wim VAN Criekinge, Bruce J Trock, et al.JMIR Cancer|August 22, 2022
Exploring Urological Malignancies on Pinterest: Content AnalysisAmber S Herbert, Naeemul Hassan, Rena D Malik, et al.Scandinavian Journal of Urology|December 23, 2021
Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancerRolf Gedeborg, Lars Lindhagen, Stacy Loeb, et al.Pageof 61